Berry Global’s market leadership in drug delivery inhalation solutions will be underlined by the company’s participation at the RDD Conference in Antibes, France in May, where Berry, together with the University of Palma’s Food and Drug Department, will present a research poster.
The project detailed in the poster aims to generate data to support a more sustainable generic dry powder inhaler (DPI) development approach. This can lead to savings on the cost of the active ingredient, lower side effects for patients, and mean a lower dispersion of the drug in the environment.
Alongside the poster, Berry will showcase its wide-ranging portfolio of DPIs and Pressurised Metered Dose inhalers (pMDIs), demonstrating some of the latest advances in usability and safety, digitalisation, and design for the circular economy.
Significant developments from Berry’s DPI range include the RS01X single dose DPI that features built-in sensors and digital services to track inhaler use and help improve adherence and technique. Also on display will be the new RS01 Size 2 capsule-based inhaler which meets the increased demand for higher dose devices for the pulmonary delivery of systemic treatments and highly engineered low density powder formulations. The RS01-R, meanwhile, is a capsule-based DPI that incorporates advanced chemical recycled resins or bio-source resins produced using the mass balance concept and which is ISCC+ certified.
Another DPI innovation will be the Berryhaler, a new Berry concept for a dual chamber multidose inhaler. This is being developed and industrialised at the company’s latest healthcare manufacturing facility in Bangalore, India.
From its the pMDI portfolio, Berry’s design and technical expertise will be demonstrated by the Pneumohaler, a new breath actuated inhaler with dose indicator. The inhaler helps to improve asthma and COPD patients’ compliance and adherence by reducing patient coordination errors and breathing variability.
To schedule a meeting with the team at RDD, email inhalation@berryglobal.com.